 |
 Video: What is a Stock Split?
|
|
|
| Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia. According to our Denali Therapeutics stock split history records, Denali Therapeutics has had 0 splits. | |
|
Denali Therapeutics (DNLI) has 0 splits in our Denali Therapeutics stock split history database.
Looking at the Denali Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Denali Therapeutics shares, starting with a $10,000 purchase of DNLI, presented on a split-history-adjusted basis factoring in the complete Denali Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/11/2017 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$20.99 |
|
| End price/share: |
$15.43 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-26.49% |
|
| Average Annual Total Return: |
-4.71% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$7,352.24 |
|
| Years: |
6.38 |
|
|
|
|
|
